Koo Jung Hoi, Song Sun Hong, Oh Ho Suk, Oh Se Hyun
Department of Rehabilitation Medicine.
Department of Internal Medicine.
Medicine (Baltimore). 2020 Mar;99(11):e19564. doi: 10.1097/MD.0000000000019564.
Although there have been some reports that hyperbaric oxygen therapy (HBOT) is effective in treating breast cancer-related lymphedema (BCRL), controversy regarding its therapeutic effects remains.We sought to evaluate the efficacy of HBOT in addition to conventional complex decongestive therapy (CDT) for BCRL.A prospective observational study was conducted on 10 patients with BCRL. After screening, the subjects were stratified into a CDT-only group and a CDT and HBOT combination (CDT-HBOT) group. All patients received a total of 10 treatments over 2 weeks. Changes in the circumference of the upper limbs, quality-of-life questionnaire results, and bioelectrical impedance values were compared between the 2 groups.Between both groups, there were no significant differences in demographic or clinical characteristics and in the quality-of-life outcomes for lymphedema of the limbs. The parameters measured by bioimpedance spectroscopy showed more significant improvements in the CDT-HBOT group than in the CDT-only group.In patients with BCRL, HBOT may be recommended as an adjunct treatment to the existing therapies.
尽管有一些报道称高压氧疗法（HBOT）在治疗乳腺癌相关淋巴水肿（BCRL）方面有效，但其治疗效果仍存在争议。我们试图评估除传统综合消肿疗法（CDT）外，HBOT对BCRL的疗效。对10例BCRL患者进行了一项前瞻性观察研究。筛选后，将受试者分为单纯CDT组和CDT与HBOT联合（CDT-HBOT）组。所有患者在2周内共接受10次治疗。比较两组上肢周长、生活质量问卷结果和生物电阻抗值的变化。两组之间在人口统计学或临床特征以及肢体淋巴水肿的生活质量结果方面没有显著差异。生物阻抗光谱测量的参数显示，CDT-HBOT组比单纯CDT组有更显著的改善。对于BCRL患者，HBOT可作为现有治疗的辅助治疗方法推荐使用。
